Tag Archives: NASDAQ:ACET

First Analysis Downgrades Adicet Bio (ACET) to Hold

In a report issued on November 14, First Analysis from First Analysis downgraded Adicet Bio (ACET – Research Report) to Hold. The company’s shares closed last Friday at $13.52, close to its 52-week low of $6.02. Adicet Bio has an

First Analysis Thinks Adicet Bio’s Stock is Going to Recover

First Analysis analyst First Analysis initiated coverage with a Buy rating on Adicet Bio (ACET – Research Report) on March 31. The company’s shares closed last Friday at $13.52, close to its 52-week low of $6.02. Adicet Bio has an

Analysts Offer Insights on Healthcare Companies: Adicet Bio (NASDAQ: ACET) and Durect (NASDAQ: DRRX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adicet Bio (ACET – Research Report) and Durect (DRRX – Research Report) with bullish sentiments. Durect (DRRX) B.Riley Financial analyst Mayank Mamtani

The SVP of Aceto Corp (NASDAQ: ACET) is Selling Shares

Today, the SVP of Aceto Corp (ACET – Research Report), Frank Debenedittis, sold shares of ACET for $9,897. See today’s analyst top recommended stocks >> Currently, Aceto Corp has an average volume of 57.54K. Frank Debenedittis’ trades have generated a

Aceto Corp Gets a Sell Rating from Canaccord Genuity

Canaccord Genuity analyst Dewey Steadman maintained a Sell rating on Aceto Corp (NASDAQ: ACET) today and set a price target of $2. The company’s shares opened today at $2.83, close to its 52-week low of $2.22. According to TipRanks.com, Steadman

Aceto Corp Receives a Buy from Canaccord Genuity

Canaccord Genuity analyst Dewey Steadman maintained a Buy rating on Aceto Corp (NASDAQ: ACET) today and set a price target of $10. The company’s shares opened today at $7.20, close to its 52-week low of $7.06. Steadman commented: “We are